Emerging regenerative treatments that help protect nerve tissue, reduce brain inflammation, and support functional recovery in patients with neurological conditions.
Neurological conditions are among the most serious and growing challenges in modern medicine. From Parkinson's disease and multiple sclerosis to stroke recovery and nerve damage, these conditions share common root mechanisms: brain inflammation, damage to the protective coating around nerves, progressive nerve loss, and permanent loss of function. The impact on mobility, thinking, and quality of life can be severe. Many patients continue to decline despite the best available care.
Conventional treatments like disease-modifying drugs for MS, dopamine medications for Parkinson's, and rehabilitation for stroke are mainly designed to slow progression or manage symptoms. They do not address the underlying neuroinflammation that keeps driving nerve damage. They also do not meaningfully support the nervous system's own repair pathways. Many patients eventually hit a ceiling with medications while continuing to decline.
Regenerative medicine, especially mesenchymal stem cell (MSC) therapy, offers a different approach. MSCs protect nerve tissue by releasing growth factors that support nerve repair, suppressing inflammatory signals in the nervous system, and creating a more healing-friendly environment in the brain and spinal cord. Early clinical research suggests these mechanisms may help in ways that conventional therapies cannot. This is an actively developing area of research. Outcomes vary by condition, stage, and patient factors. No claims of cure or disease reversal are made.
Current research supports the investigational use of regenerative protocols for several neurological conditions. Approaches are tailored to each condition.
MSC-derived growth factors may support the brain's ability to reorganize and repair itself after a stroke. Evidence suggests this approach is most beneficial in the first six months after a stroke, when the brain's plasticity is highest.
MS is an inflammatory condition where the immune system attacks the protective coating around nerve fibers. MSC therapy may reduce relapse frequency and lower the neuroinflammatory burden in patients with early to moderate disease. These protocols are investigational and most applicable before significant nerve damage has occurred.
Parkinsonian syndromes involve the loss of dopamine-producing nerve cells and progressive motor decline. Early research suggests that protective signals from MSCs may help slow this progression. Improved motor scores have been reported in small clinical trials. This is still an emerging application area.
Peripheral neuropathy from diabetes, chemotherapy, or injury can cause pain, numbness, and weakness. MSC-derived exosomes support nerve cell repair and regeneration, offering a targeted approach for conditions where conventional treatments provide limited relief.
A personalized protocol built through a thorough neurological assessment, imaging review, and collaborative planning with our clinical team.
We review available imaging of the brain and spinal cord, validated scoring tools for your specific condition, medication history, and your full disease timeline. This baseline establishes your current function and helps identify the most appropriate regenerative approach for your diagnosis and stage.
Based on your assessment, we select the right delivery method. IV infusion is used for systemic conditions like MS. More targeted delivery routes are used for conditions requiring direct access to the nervous system. The method is chosen based on your condition, disease stage, and physician judgment.
All procedures are outpatient. Standard IV infusions take 2 to 4 hours. More targeted delivery methods are performed in a licensed clinical setting with appropriate monitoring. All cell preparations come from rigorously screened, certified providers.
We re-evaluate your condition at 6 to 12 weeks after treatment using validated neurological assessment tools. Repeat imaging or functional testing is ordered as needed. Our team coordinates with your existing neurologist throughout the monitoring period.
Neurological response to regenerative therapy develops gradually. This timeline reflects patterns observed in clinical experience and research. Individual outcomes vary by condition, stage, and patient factors.
Systemic inflammatory markers begin improving. Some patients report reduced fatigue, better sleep, and mild functional gains as brain inflammation begins to shift.
Growth factors support the nerve tissue environment. Subtle improvements in motor function, thinking, or sensation may begin to emerge depending on the condition being treated.
Patients who respond well typically notice measurable improvements in function, mobility, or symptoms during this phase. We use validated scoring tools to objectively track these changes from baseline.
Our clinical team evaluates treatment response using validated neurological assessments. Additional sessions are considered based on individual outcomes, disease trajectory, and physician recommendation.
Talk with our clinical team to find out if regenerative therapy is right for your neurological condition and goals.
Book Your Consultation →